| scholarly article | Q13442814 |
| P2093 | author name string | Ji-Hyun Lee | |
| Thomas A Hensing | |||
| Michael J Schell | |||
| Mark A Socinski | |||
| Amy H Peterman | |||
| P2860 | cites work | Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer | Q29615476 |
| Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report | Q30583610 | ||
| Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trial | Q30626561 | ||
| The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study | Q31963937 | ||
| Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions | Q33495769 | ||
| Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors | Q36114807 | ||
| Differences in initial treatment patterns and outcomes of lung cancer in the elderly. | Q39426048 | ||
| Clinical aspects of cancer in the elderly. Treatment decisions, treatment choices, and follow-up | Q40704624 | ||
| Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial | Q43658480 | ||
| Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial | Q43878521 | ||
| Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel | Q44128414 | ||
| A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort | Q45114668 | ||
| Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer | Q53517685 | ||
| Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer | Q60685440 | ||
| Patterns of practice survey for nonsmall cell lung carcinoma in the U.S. | Q64882392 | ||
| Underrepresentation of patients 65 years of age or older in cancer-treatment trials | Q73311140 | ||
| Who gets chemotherapy for metastatic lung cancer? | Q73783430 | ||
| Cisplatin-based combination chemotherapy for elderly patients with non-small-cell lung cancer | Q73793452 | ||
| Management of cancer in the older person: a practical approach | Q73964368 | ||
| Retrospective comparison of toxicity and efficacy in phase II trials of 3-h infusions of paclitaxel for patients 70 years of age or older and patients under 70 years of age | Q74266049 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | paclitaxel | Q423762 |
| quality of life | Q13100823 | ||
| carboplatin | Q415588 | ||
| lung carcinoma | Q18556110 | ||
| P1104 | number of pages | 10 | |
| P304 | page(s) | 779-788 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel | |
| P478 | volume | 98 |
| Q53236914 | A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer |
| Q33401712 | A meta analysis of doublets versus single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer |
| Q41560445 | A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer |
| Q50976979 | A retrospective analysis comparing the safety and efficacy of chemotherapy in elderly and non‐elderly non‐small‐cell lung cancer patients |
| Q38233740 | A review of the management of elderly patients with non-small-cell lung cancer. |
| Q36715269 | Adjuvant chemotherapy in elderly patients with non-small-cell lung cancer |
| Q33628784 | Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer |
| Q58587248 | Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101 |
| Q47139009 | Air Quality Effects on Human Health and Approaches for Its Assessment through Microfluidic Chips |
| Q84911213 | American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer |
| Q34401471 | Association of patient characteristics with chemotherapy receipt among depressed and non-depressed patients with non-small cell lung cancer |
| Q35894352 | Biological, clinical, and psychosocial correlates at the interface of cancer and aging research |
| Q33396438 | Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study |
| Q35980560 | Chemotherapy in elderly patients with advanced lung cancer. Part II: Treatment of non-small cell lung cancer (NSCLC). |
| Q37939963 | Chemotherapy treatment decision making by professionals and older patients with cancer: a narrative review of the literature |
| Q33402852 | Cisplatin-Based Therapy for the Treatment of Elderly Patients with Non-Small-Cell Lung Cancer: a Retrospective Analysis of a Single Institution |
| Q34786733 | Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years: An Analysis of Southwest Oncology Group Trials 9308 and 9509 |
| Q50876120 | Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors |
| Q37231992 | Development of a novel location-based assessment of sensory symptoms in cancer patients: preliminary reliability and validity assessment |
| Q84334520 | Docetaxel Vs. Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: A Hellenic Oncology Research Group Randomized Phase III Study |
| Q33401852 | Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis |
| Q33411167 | Doublets versus single-agent therapy as first-line therapy for elderly patients with advanced non-small cell lung cancer? A systematic review of randomised controlled trials |
| Q37589341 | EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. |
| Q33396073 | Effect of age on systemic exposure and haematological toxicity of carboplatin in advanced non-small cell lung cancer patients |
| Q47601358 | Elderly patients with squamous lung carcinoma: faring better or worse? |
| Q47376469 | Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study |
| Q33398466 | Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer |
| Q84464655 | Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer |
| Q36695414 | Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients |
| Q33383403 | Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis |
| Q35076356 | Health-related quality of life and cancer clinical trials |
| Q36884830 | Health-related quality of life questionnaires in lung cancer trials: a systematic literature review |
| Q92048522 | Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact |
| Q36058277 | Impact of Age and Comorbidity on Non–Small-Cell Lung Cancer Treatment in Older Veterans |
| Q37242517 | Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials |
| Q37486185 | NSCLC in the elderly--the legacy of therapeutic neglect |
| Q52848876 | Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). |
| Q33429178 | Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer |
| Q89848254 | Performance Status and Age as Predictors of Immunotherapy Outcomes in Advanced Non-Small-Cell Lung Cancer |
| Q38386745 | Pharmacotherapy for treatment of lung cancer in the elderly |
| Q28539449 | Prediction of cancer drugs by chemical-chemical interactions |
| Q53232749 | Quality of life in newly diagnosed patients with lung cancer in a developing country: is it important? |
| Q53264293 | Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice |
| Q35076283 | Review: Treating advanced non-small cell lung cancer in the elderly |
| Q36299985 | Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients |
| Q28303620 | The Lake Wobegon effect: are all cancer patients above average? |
| Q36276360 | Treatment of elderly cancer patients with chemotherapy |
| Q81154285 | Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network |
| Q84643820 | [American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer] |
Search more.